首页 > 最新文献

JID innovations : skin science from molecules to population health最新文献

英文 中文
Skin & Digital: The 2023 Startups/Innovators 皮肤与数字2023 年初创企业/创新者
Pub Date : 2024-09-19 DOI: 10.1016/j.xjidi.2024.100316
Dominique du Crest , Philipp Wustrow , Oliver Worsley , Barbara Geusens , Omar Badri , Monisha Madhumita , Art Papier , Alexander Zink , Merete Hædersdal , Lilit Garibyan
{"title":"Skin & Digital: The 2023 Startups/Innovators","authors":"Dominique du Crest , Philipp Wustrow , Oliver Worsley , Barbara Geusens , Omar Badri , Monisha Madhumita , Art Papier , Alexander Zink , Merete Hædersdal , Lilit Garibyan","doi":"10.1016/j.xjidi.2024.100316","DOIUrl":"10.1016/j.xjidi.2024.100316","url":null,"abstract":"","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 1","pages":"Article 100316"},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142440949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in Microengineered Platforms for Skin Research 微工程皮肤研究平台的进展
Pub Date : 2024-09-18 DOI: 10.1016/j.xjidi.2024.100315
Sireesh Kumar Teertam , Vijayasaradhi Setaluri , Jose M. Ayuso
The skin plays a critical role in human physiology, acting both as a barrier to environmental insults and as a window to environmental stimuli. Disruption of this homeostasis leads to numerous skin disorders. Human and animal skin differ significantly, limiting the translational potential of animal-based investigations to advance therapeutics to human skin diseases. Hence, there is a critical need for physiologically relevant human skin models to explore novel treatment strategies. Recent advances in microfluidic technologies now allow design and generation of organ-on-chip devices that mimic critical features of tissue architecture. Skin-on-a-chip and microfluidic platforms hold promise as useful models for diverse dermatology applications. Compared with traditional in vitro models, microfluidic platforms offer improved control of fluid flow, which in turn allows precise manipulation of cell and molecular distribution. These properties enable the generation of multilayered in vitro models that mimic human skin structure while simultaneously offering superior control over nutrient and drug distribution. Researchers have used microfluidic platforms for a variety of applications in skin research, including epidermal–dermal cellular crosstalk, cell migration, mechanobiology, microbiome–immune response interactions, vascular biology, and wound healing. In this review, we comprehensively review state-of-the-art microfluidic models for skin research. We discuss the challenges and promise of current skin-on-a-chip technologies and provide a roadmap for future research in this active field.
皮肤在人体生理中起着至关重要的作用,它既是抵御环境伤害的屏障,也是接受环境刺激的窗口。这种平衡状态的破坏会导致许多皮肤疾病。人类和动物的皮肤差异很大,这限制了以动物为基础的研究在促进人类皮肤病治疗方面的转化潜力。因此,亟需与生理相关的人类皮肤模型来探索新的治疗策略。微流体技术的最新进展现在可以设计和生成模拟组织结构关键特征的片上器官装置。片上皮肤和微流控平台有望成为各种皮肤病学应用的有用模型。与传统的体外模型相比,微流体平台能更好地控制流体流动,进而精确控制细胞和分子的分布。这些特性使多层体外模型得以产生,在模仿人体皮肤结构的同时,还能对营养物质和药物的分布进行出色的控制。研究人员已将微流控平台用于皮肤研究的多种应用,包括表皮-真皮细胞串联、细胞迁移、机械生物学、微生物-免疫反应相互作用、血管生物学和伤口愈合。在这篇综述中,我们全面回顾了最先进的皮肤研究微流控模型。我们讨论了当前片上皮肤技术所面临的挑战和前景,并为这一活跃领域的未来研究提供了路线图。
{"title":"Advances in Microengineered Platforms for Skin Research","authors":"Sireesh Kumar Teertam ,&nbsp;Vijayasaradhi Setaluri ,&nbsp;Jose M. Ayuso","doi":"10.1016/j.xjidi.2024.100315","DOIUrl":"10.1016/j.xjidi.2024.100315","url":null,"abstract":"<div><div>The skin plays a critical role in human physiology, acting both as a barrier to environmental insults and as a window to environmental stimuli. Disruption of this homeostasis leads to numerous skin disorders. Human and animal skin differ significantly, limiting the translational potential of animal-based investigations to advance therapeutics to human skin diseases. Hence, there is a critical need for physiologically relevant human skin models to explore novel treatment strategies. Recent advances in microfluidic technologies now allow design and generation of organ-on-chip devices that mimic critical features of tissue architecture. Skin-on-a-chip and microfluidic platforms hold promise as useful models for diverse dermatology applications. Compared with traditional in vitro models, microfluidic platforms offer improved control of fluid flow, which in turn allows precise manipulation of cell and molecular distribution. These properties enable the generation of multilayered in vitro models that mimic human skin structure while simultaneously offering superior control over nutrient and drug distribution. Researchers have used microfluidic platforms for a variety of applications in skin research, including epidermal–dermal cellular crosstalk, cell migration, mechanobiology, microbiome–immune response interactions, vascular biology, and wound healing. In this review, we comprehensively review state-of-the-art microfluidic models for skin research. We discuss the challenges and promise of current skin-on-a-chip technologies and provide a roadmap for future research in this active field.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 1","pages":"Article 100315"},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142554849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcriptomic Analyses Predict Enhanced Metabolic Activity and Therapeutic Potential of mTOR Inhibitors in Acne-Prone Skin 转录组分析预测了 mTOR 抑制剂在痤疮皮肤中增强的代谢活性和治疗潜力
Pub Date : 2024-09-07 DOI: 10.1016/j.xjidi.2024.100306
Mackenzie L. Sennett , George W. Agak , Diane M. Thiboutot , Amanda M. Nelson

Current acne therapies center on preventing new lesions in patients with acne. These therapies were historically found to be beneficial yet were chosen without knowledge of the specific changes in the skin that favor lesion development. A major challenge in developing new treatments is the incomplete understanding of nonlesional (NL), acne-prone skin’s molecular characteristics. To address this, we compared RNA-sequencing data from NL skin of 49 patients with acne (denoted as NL acne [NLA]) with those from 19 healthy controls with no acne history. We found 77 differentially expressed genes in NLA (log fold change > 1; P < .05), including genes associated with innate immunity and epidermal barrier function. Notably, KRT6C, KRT16, S100A8, S100A9, and lactotransferrin were upregulated, and LCE4A, LCE6A, and CTSE were downregulated. Gene set enrichment analysis revealed that metabolic pathways were enriched in NLA skin, whereas keratinization was negatively enriched. To identify compounds that could shift the gene expression signature of NLA skin toward healthy control skin, we performed connectivity mapping with the Library of Integrated Network-Based Signatures. We identified 187 compounds, particularly mTOR inhibitors, that could potentially normalize the gene expression profile of acne-prone skin to that of healthy skin. Our findings indicate that NLA skin has distinct differences in epidermal differentiation, cellular metabolism, and innate immunity that may promote lesion formation and suggest that mTOR inhibitors could restore NLA skin toward a healthier state, potentially reversing the predisposition to lesion development.

目前的痤疮疗法主要是防止痤疮患者出现新的皮损。这些疗法历来被认为是有益的,但在选择这些疗法时,人们并不了解有利于皮损发展的皮肤的具体变化。开发新疗法面临的一大挑战是对非皮损性(NL)痤疮易发皮肤分子特征的不完全了解。为了解决这个问题,我们比较了 49 名痤疮患者(简称为 NL 型痤疮 [NLA])的 NL 型皮肤与 19 名无痤疮史的健康对照者的 RNA 序列数据。我们在 NLA 中发现了 77 个差异表达基因(对数折叠变化为 1;P 为 0.05),其中包括与先天免疫和表皮屏障功能相关的基因。值得注意的是,KRT6C、KRT16、S100A8、S100A9 和乳转铁蛋白被上调,而 LCE4A、LCE6A 和 CTSE 被下调。基因组富集分析表明,新陈代谢途径在 NLA 皮肤中富集,而角质化则呈负富集。为了找出能使 NLA 皮肤的基因表达特征向健康对照皮肤转变的化合物,我们利用基于综合网络特征库进行了连接图谱分析。我们发现了 187 种化合物,尤其是 mTOR 抑制剂,它们有可能使痤疮皮肤的基因表达谱正常化,与健康皮肤的基因表达谱一致。我们的研究结果表明,NLA 皮肤在表皮分化、细胞代谢和先天性免疫方面存在明显差异,这些差异可能会促进皮损的形成。
{"title":"Transcriptomic Analyses Predict Enhanced Metabolic Activity and Therapeutic Potential of mTOR Inhibitors in Acne-Prone Skin","authors":"Mackenzie L. Sennett ,&nbsp;George W. Agak ,&nbsp;Diane M. Thiboutot ,&nbsp;Amanda M. Nelson","doi":"10.1016/j.xjidi.2024.100306","DOIUrl":"10.1016/j.xjidi.2024.100306","url":null,"abstract":"<div><p>Current acne therapies center on preventing new lesions in patients with acne. These therapies were historically found to be beneficial yet were chosen without knowledge of the specific changes in the skin that favor lesion development. A major challenge in developing new treatments is the incomplete understanding of nonlesional (NL), acne-prone skin’s molecular characteristics. To address this, we compared RNA-sequencing data from NL skin of 49 patients with acne (denoted as NL acne [NLA]) with those from 19 healthy controls with no acne history. We found 77 differentially expressed genes in NLA (log fold change &gt; 1; <em>P</em> &lt; .05), including genes associated with innate immunity and epidermal barrier function. Notably, <em>K</em><em>RT</em><em>6C</em>, <em>K</em><em>RT</em><em>16</em>, <em>S100A8</em>, <em>S100A9</em>, and lactotransferrin were upregulated<em>,</em> and <em>LCE4A, LCE6A,</em> and <em>CTSE</em> were downregulated<em>.</em> Gene set enrichment analysis revealed that metabolic pathways were enriched in NLA skin, whereas keratinization was negatively enriched. To identify compounds that could shift the gene expression signature of NLA skin toward healthy control skin, we performed connectivity mapping with the Library of Integrated Network-Based Signatures. We identified 187 compounds, particularly mTOR inhibitors, that could potentially normalize the gene expression profile of acne-prone skin to that of healthy skin. Our findings indicate that NLA skin has distinct differences in epidermal differentiation, cellular metabolism, and innate immunity that may promote lesion formation and suggest that mTOR inhibitors could restore NLA skin toward a healthier state, potentially reversing the predisposition to lesion development.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 6","pages":"Article 100306"},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026724000535/pdfft?md5=d23043e7c7fe4614bbbea701eaadc7a9&pid=1-s2.0-S2667026724000535-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142173030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study 大麻素受体 2 型激动剂 Lenabasum 对患有难治性皮肤病的皮肌炎患者的长期安全性和疗效:一项为期 3 年的开放标签扩展研究的随访数据
Pub Date : 2024-09-05 DOI: 10.1016/j.xjidi.2024.100311
Caroline J. Stone , Geeta Ahuja , Lais Lopes Almeida Gomes , Joy Poroye , Daniella Forman Faden , Lillian Xie , Rui Feng , Barbara White , Victoria P. Werth

Background

Dermatomyositis (DM) is a rare autoimmune condition involving skin manifestations often resistant to standard treatments such as immunosuppressants and antimalarials. Biopsies show elevated inflammatory cells such as CD4+ T cells, dendritic cells, and cytokines. Lenabasum, a selective cannabinoid receptor 2 agonist, has demonstrated significant benefits in treating autoimmune skin diseases. Objectives: This study utilizes data from the open-label extension (OLE) phase of the lenabasum phase 2 trial and additional post-OLE follow-up data. Key aims include evaluating the drug’s long-term effectiveness and assessing disease manifestation recurrence. Methods: The phase 2 lenabasum trial enrolled patients with treatment-resistant, skin-predominant DM. The OLE consisted of a 3-year period during which 20 patients were on the drug for the entire duration, with assessments every 8 weeks to evaluate drug safety and efficacy. Subsequently, a follow-up retrospective chart review was performed on patients who completed the OLE as well as on control subjects with DM who did not participate in the lenabasum trial. Results: By week 68, patients exhibited reductions in Cutaneous Dermatomyositis Disease Area and Severity Index activity score (−21.8), Patient Skin Activity Visual Analog Scale (−3.0), and Skindex-29 (−28.0) from OLE baseline. After OLE, 58.3% maintained stable disease, significantly higher than controls (P = .035), with 41.7% not experiencing flares compared with 91.6% of controls. In addition, 50% of patients reported sustained pruritus improvement. Conclusions: Data from OLE and subsequent follow-up periods demonstrate lenabasum’s efficacy in maintaining disease stability, reducing flares, and improving DM symptoms, suggesting that it is a promising option for patients with treatment-resistant skin-predominant DM. Trial Registration: This study was registered at clinicaltrials.gov, with NCT02466243. Study registration was first submitted on June 2, 2015.
背景皮肌炎(Dermatomyositis,DM)是一种罕见的自身免疫性疾病,患者的皮肤表现往往对免疫抑制剂和抗疟药等标准疗法产生抗药性。活组织检查显示 CD4+ T 细胞、树突状细胞和细胞因子等炎症细胞升高。莱那巴苏姆是一种选择性大麻素受体 2 激动剂,在治疗自身免疫性皮肤病方面有显著疗效。研究目的本研究利用来那巴苏姆二期试验开放标签延长(OLE)阶段的数据以及开放标签延长后的额外随访数据。主要目的包括评估该药物的长期疗效和疾病复发情况。研究方法来那巴苏姆2期试验招募了耐药的皮肤型DM患者。OLE为期3年,20名患者全程用药,每8周进行一次评估,以评价药物的安全性和有效性。随后,我们对完成OLE的患者以及未参加来那巴苏试验的DM对照组患者进行了随访回顾性病历审查。结果显示到第68周时,患者的皮肤皮肌炎疾病面积和严重程度指数活动评分(-21.8)、患者皮肤活动视觉模拟量表(-3.0)和Skindex-29(-28.0)与OLE基线相比均有所下降。OLE后,58.3%的患者病情保持稳定,明显高于对照组(P = 0.035),41.7%的患者没有复发,而对照组的这一比例为91.6%。此外,50% 的患者报告瘙痒症状持续改善。结论:来自OLE和后续随访期的数据表明来那巴苏在维持病情稳定、减少复发和改善DM症状方面具有疗效,这表明它是皮肤为主的DM耐药患者的一个很有前景的选择。试验注册:该研究已在 clinicaltrials.gov 注册,注册号为 NCT02466243。研究注册于2015年6月2日首次提交。
{"title":"Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study","authors":"Caroline J. Stone ,&nbsp;Geeta Ahuja ,&nbsp;Lais Lopes Almeida Gomes ,&nbsp;Joy Poroye ,&nbsp;Daniella Forman Faden ,&nbsp;Lillian Xie ,&nbsp;Rui Feng ,&nbsp;Barbara White ,&nbsp;Victoria P. Werth","doi":"10.1016/j.xjidi.2024.100311","DOIUrl":"10.1016/j.xjidi.2024.100311","url":null,"abstract":"<div><h3>Background</h3><div>Dermatomyositis (DM) is a rare autoimmune condition involving skin manifestations often resistant to standard treatments such as immunosuppressants and antimalarials. Biopsies show elevated inflammatory cells such as CD4+ T cells, dendritic cells, and cytokines. Lenabasum, a selective cannabinoid receptor 2 agonist, has demonstrated significant benefits in treating autoimmune skin diseases. Objectives: This study utilizes data from the open-label extension (OLE) phase of the lenabasum phase 2 trial and additional post-OLE follow-up data. Key aims include evaluating the drug’s long-term effectiveness and assessing disease manifestation recurrence. Methods: The phase 2 lenabasum trial enrolled patients with treatment-resistant, skin-predominant DM. The OLE consisted of a 3-year period during which 20 patients were on the drug for the entire duration, with assessments every 8 weeks to evaluate drug safety and efficacy. Subsequently, a follow-up retrospective chart review was performed on patients who completed the OLE as well as on control subjects with DM who did not participate in the lenabasum trial. Results: By week 68, patients exhibited reductions in Cutaneous Dermatomyositis Disease Area and Severity Index activity score (−21.8), Patient Skin Activity Visual Analog Scale (−3.0), and Skindex-29 (−28.0) from OLE baseline. After OLE, 58.3% maintained stable disease, significantly higher than controls (<em>P</em> = .035), with 41.7% not experiencing flares compared with 91.6% of controls. In addition, 50% of patients reported sustained pruritus improvement. Conclusions: Data from OLE and subsequent follow-up periods demonstrate lenabasum’s efficacy in maintaining disease stability, reducing flares, and improving DM symptoms, suggesting that it is a promising option for patients with treatment-resistant skin-predominant DM. Trial Registration: This study was registered at <span><span>clinicaltrials.gov</span><svg><path></path></svg></span>, with <span><span>NCT02466243</span><svg><path></path></svg></span>. Study registration was first submitted on June 2, 2015.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 1","pages":"Article 100311"},"PeriodicalIF":0.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142358428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Type 2 Cytokine–Dependent Skin Barrier Regulation in Personalized 2-Dimensional and 3-Dimensional Skin Models of Atopic Dermatitis: A Pilot Study 特应性皮炎个性化二维和三维皮肤模型中的 2 型细胞因子依赖性皮肤屏障调节:试点研究
Pub Date : 2024-08-30 DOI: 10.1016/j.xjidi.2024.100309
Hila Emmert , Franziska Rademacher , Matthias Hübenthal , Regine Gläser , Hanne Norsgaard , Stephan Weidinger , Jürgen Harder
Keratinocytes (KCs) from healthy donors stimulated with type 2 cytokines are often used to experimentally study atopic dermatitis (AD) inflammatory responses. Owing to potential intrinsic alterations, it seems favorable to use KCs from patients with AD. KCs isolated from hair follicles offer a noninvasive approach to investigate AD-derived KCs. To evaluate whether such AD-derived KCs are suitable to mimic AD inflammatory responses, we compared hair follicle–derived KCs from healthy donors with those from patients with AD in a type 2 cytokine environment. Stimulation of AD-derived KCs with IL-4 and IL-13 induced higher expression changes of AD-associated markers than that of healthy KCs. The combination of IL-4 and IL-13 generally induced highest expression changes, but IL-13 alone also induced significant changes of AD-specific markers. Similar to the 2-dimensional cultures, IL-4/IL-13 stimulation of 3-dimensional skin models generated with AD-derived KCs modulated the expression of several AD-relevant factors. Whole-transcriptome analysis revealed that IL-4 and IL-13 acted similarly on these 3-dimensional skin models. Histologically, IL-13 alone and in combination with IL-4 increased epidermal spongiosis, a histological hallmark of AD skin. Taken together, our pilot study suggests that hair follicle–derived KCs from patients with AD represent a useful model system to study AD-related inflammation in a personalized in vitro model.
用 2 型细胞因子刺激健康供体的角质形成细胞(KCs)通常被用于特应性皮炎(AD)炎症反应的实验研究。由于潜在的内在改变,使用特应性皮炎患者的角质形成细胞似乎更为有利。从毛囊中分离出的 KC 为研究 AD 衍生的 KC 提供了一种非侵入性的方法。为了评估这种 AD 衍生的 KCs 是否适合模拟 AD 的炎症反应,我们比较了在 2 型细胞因子环境中来自健康供体的毛囊衍生 KCs 和来自 AD 患者的毛囊衍生 KCs。与健康KCs相比,用IL-4和IL-13刺激AD衍生KCs会诱发更高的AD相关标记物表达变化。一般来说,IL-4和IL-13的组合能诱导最高的表达变化,但单独使用IL-13也能诱导AD特异性标记物的显著变化。与二维培养相似,IL-4/IL-13刺激由AD衍生KCs生成的三维皮肤模型也会调节多种AD相关因子的表达。全转录组分析表明,IL-4和IL-13对这些三维皮肤模型的作用类似。从组织学角度看,IL-13单独或与IL-4联合使用都会增加表皮海绵状增生,这是AD皮肤的组织学特征。综上所述,我们的试验性研究表明,来自AD患者的毛囊衍生KC是在个性化体外模型中研究AD相关炎症的有用模型系统。
{"title":"Type 2 Cytokine–Dependent Skin Barrier Regulation in Personalized 2-Dimensional and 3-Dimensional Skin Models of Atopic Dermatitis: A Pilot Study","authors":"Hila Emmert ,&nbsp;Franziska Rademacher ,&nbsp;Matthias Hübenthal ,&nbsp;Regine Gläser ,&nbsp;Hanne Norsgaard ,&nbsp;Stephan Weidinger ,&nbsp;Jürgen Harder","doi":"10.1016/j.xjidi.2024.100309","DOIUrl":"10.1016/j.xjidi.2024.100309","url":null,"abstract":"<div><div>Keratinocytes (KCs) from healthy donors stimulated with type 2 cytokines are often used to experimentally study atopic dermatitis (AD) inflammatory responses. Owing to potential intrinsic alterations, it seems favorable to use KCs from patients with AD. KCs isolated from hair follicles offer a noninvasive approach to investigate AD-derived KCs. To evaluate whether such AD-derived KCs are suitable to mimic AD inflammatory responses, we compared hair follicle–derived KCs from healthy donors with those from patients with AD in a type 2 cytokine environment. Stimulation of AD-derived KCs with IL-4 and IL-13 induced higher expression changes of AD-associated markers than that of healthy KCs. The combination of IL-4 and IL-13 generally induced highest expression changes, but IL-13 alone also induced significant changes of AD-specific markers. Similar to the 2-dimensional cultures, IL-4/IL-13 stimulation of 3-dimensional skin models generated with AD-derived KCs modulated the expression of several AD-relevant factors. Whole-transcriptome analysis revealed that IL-4 and IL-13 acted similarly on these 3-dimensional skin models. Histologically, IL-13 alone and in combination with IL-4 increased epidermal spongiosis, a histological hallmark of AD skin. Taken together, our pilot study suggests that hair follicle–derived KCs from patients with AD represent a useful model system to study AD-related inflammation in a personalized in vitro model.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 1","pages":"Article 100309"},"PeriodicalIF":0.0,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142323252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Keratinocyte Integrin α3β1 Promotes Efficient Healing of Wound Epidermis 角质细胞整合素 α3β1 促进伤口表皮的有效愈合
Pub Date : 2024-08-29 DOI: 10.1016/j.xjidi.2024.100310
Sanjana Dhulipalla , Giesse Albeche Duarte , Lei Wu , Mathieu R. DiPersio , John M. Lamar , C. Michael DiPersio , Whitney M. Longmate
To date, studies of the role for epidermal integrin α3β1 in cutaneous wound re-epithelialization have produced conflicting results: wound studies in skin from global α3-null neonatal mice have implicated the integrin in promoting timely wound re-epithelialization, whereas studies in adult mice with constitutive, epidermal-specific α3β1 deletion have not. The objective of this study was to utilize a model of inducible α3β1 deletion in the epidermis to clarify the role of α3β1 in the healing of adult wounds. We utilized the recently developed transgenic K14Cre-ERT::α3flx/flx mice (ie, inducible α3 epidermal knockout), permitting us to delete floxed Itga3 alleles (α3flx/flx) from epidermis just prior to wounding with topical treatment of 4-hydroxytamoxifen. This allows for the elucidation of α3β1-dependent wound healing in adult skin, free from compensatory mechanisms that may occur after embryonic deletion of epidermal α3β1 in the widely used constitutive α3β1-knockout mouse. We found that re-epithelializing wound gaps are larger in inducible α3 epidermal knockout mice than in control mice, indicating delayed healing, and that epidermal integrin α3β1 promotes healing of wounds, at least in part by enhancing keratinocyte proliferation. This work provides essential rationale for future studies to investigate integrin α3β1 as a therapeutic target to facilitate wound healing.
迄今为止,有关表皮整合素α3β1在皮肤伤口再上皮化中的作用的研究得出了相互矛盾的结果:对全基因α3缺失的新生小鼠皮肤伤口的研究表明,整合素能促进伤口及时再上皮化,而对组成型表皮特异性α3β1缺失的成年小鼠的研究则没有发现这种作用。本研究的目的是利用表皮中可诱导的α3β1缺失模型来阐明α3β1在成人伤口愈合中的作用。我们利用最近开发的转基因K14Cre-ERT::α3flx/flx小鼠(即诱导性α3表皮基因敲除),在使用4-羟基他莫昔芬局部处理伤口之前,从表皮中删除浮性Itga3等位基因(α3flx/flx)。这样就可以阐明成年皮肤中α3β1依赖性伤口愈合的情况,而不需要考虑广泛使用的组成型α3β1基因敲除小鼠胚胎期缺失表皮α3β1后可能出现的代偿机制。我们发现,诱导性α3表皮基因敲除小鼠的伤口再表皮化间隙比对照小鼠大,表明伤口愈合延迟,表皮整合素α3β1至少部分通过增强角质形成细胞的增殖来促进伤口愈合。这项工作为今后研究将整合素α3β1作为促进伤口愈合的治疗靶点提供了重要依据。
{"title":"Keratinocyte Integrin α3β1 Promotes Efficient Healing of Wound Epidermis","authors":"Sanjana Dhulipalla ,&nbsp;Giesse Albeche Duarte ,&nbsp;Lei Wu ,&nbsp;Mathieu R. DiPersio ,&nbsp;John M. Lamar ,&nbsp;C. Michael DiPersio ,&nbsp;Whitney M. Longmate","doi":"10.1016/j.xjidi.2024.100310","DOIUrl":"10.1016/j.xjidi.2024.100310","url":null,"abstract":"<div><div>To date, studies of the role for epidermal integrin α3β1 in cutaneous wound re-epithelialization have produced conflicting results: wound studies in skin from global α3-null neonatal mice have implicated the integrin in promoting timely wound re-epithelialization, whereas studies in adult mice with constitutive, epidermal-specific α3β1 deletion have not. The objective of this study was to utilize a model of inducible α3β1 deletion in the epidermis to clarify the role of α3β1 in the healing of adult wounds. We utilized the recently developed transgenic K14<sup>Cre-ERT</sup>::α3<sup>flx/flx</sup> mice (ie, inducible α3 epidermal knockout), permitting us to delete floxed <em>Itga3</em> alleles (α3<sup>flx/flx</sup>) from epidermis just prior to wounding with topical treatment of 4-hydroxytamoxifen. This allows for the elucidation of α3β1-dependent wound healing in adult skin, free from compensatory mechanisms that may occur after embryonic deletion of epidermal α3β1 in the widely used constitutive α3β1-knockout mouse. We found that re-epithelializing wound gaps are larger in inducible α3 epidermal knockout mice than in control mice, indicating delayed healing, and that epidermal integrin α3β1 promotes healing of wounds, at least in part by enhancing keratinocyte proliferation. This work provides essential rationale for future studies to investigate integrin α3β1 as a therapeutic target to facilitate wound healing.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 1","pages":"Article 100310"},"PeriodicalIF":0.0,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142318704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study 阿夫多拉单抗治疗大疱性类天疱疮:多中心、随机、开放标签 2 期研究
Pub Date : 2024-08-23 DOI: 10.1016/j.xjidi.2024.100307
Thierry Passeron , Eric Fontas , Thierry Boye , Marie-Aleth Richard , Emmanuel Delaporte , Olivier Dereure

Rationale: Experimental data support the role for C5a–C5aR1 axis activation in bullous pemphigoid. We assessed the efficacy and safety of avdoralimab, a specific anti-C5aR1 mAb, for treating bullous pemphigoid. Methods: We conducted a phase 2 open-labeled randomized multicenter study. Patients with proven bullous pemphigoid were randomized (1:1) to receive superpotent topical steroids alone (group A) or with avdoralimab (group B). All patients received 0.05% clobetasol propionate cream until 15 days after the healing of lesions. Patients in group B additionally received 3 injections of avdoralimab every week for 12 weeks. The main criterion of evaluation was the proportion of patients with initial control of disease activity still in complete clinical remission at 3 months with no relapse during the study period. Results: Fifteen patients were randomized: 7 to group A and 8 to group B. Two patients in group A and in group B achieved control of disease activity at week 4. Only 1 patient was still in complete clinical remission at week 12 in group B, and none was in group A. No adverse event related to the treatment was reported. Conclusions: This proof-of-concept pilot study did not show preliminary signal of additional avdoralimab efficiency compared with superpotent topical steroids alone.

理由:实验数据支持 C5a-C5aR1 轴激活在大疱性类天疱疮中的作用。我们评估了阿杜拉单抗(一种特异性抗 C5aR1 mAb)治疗大疱性类天疱疮的有效性和安全性。研究方法我们进行了一项二期开放标签随机多中心研究。经证实患有大疱性类天疱疮的患者被随机(1:1)分为单独接受超强局部类固醇(A 组)或联合阿多拉单抗(B 组)两组。所有患者均使用 0.05% 丙酸氯倍他索乳膏,直至皮损愈合后 15 天。B 组患者每周额外注射 3 次阿杜拉单抗,持续 12 周。评估的主要标准是初步控制了疾病活动的患者在 3 个月后仍处于完全临床缓解且在研究期间没有复发的比例。研究结果A组和B组分别有两名患者在第4周时疾病活动得到控制。B 组中只有 1 名患者在第 12 周时仍处于完全临床缓解状态,而 A 组中则没有。结论:这是一项概念验证试验研究:这项概念验证试验研究并未显示出阿夫多拉单抗比单用超强效局部类固醇药物更有效的初步信号。
{"title":"Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study","authors":"Thierry Passeron ,&nbsp;Eric Fontas ,&nbsp;Thierry Boye ,&nbsp;Marie-Aleth Richard ,&nbsp;Emmanuel Delaporte ,&nbsp;Olivier Dereure","doi":"10.1016/j.xjidi.2024.100307","DOIUrl":"10.1016/j.xjidi.2024.100307","url":null,"abstract":"<div><p>Rationale: Experimental data support the role for C5a–C5aR1 axis activation in bullous pemphigoid. We assessed the efficacy and safety of avdoralimab, a specific anti-C5aR1 mAb, for treating bullous pemphigoid. Methods: We conducted a phase 2 open-labeled randomized multicenter study. Patients with proven bullous pemphigoid were randomized (1:1) to receive superpotent topical steroids alone (group A) or with avdoralimab (group B). All patients received 0.05% clobetasol propionate cream until 15 days after the healing of lesions. Patients in group B additionally received 3 injections of avdoralimab every week for 12 weeks. The main criterion of evaluation was the proportion of patients with initial control of disease activity still in complete clinical remission at 3 months with no relapse during the study period. Results: Fifteen patients were randomized: 7 to group A and 8 to group B. Two patients in group A and in group B achieved control of disease activity at week 4. Only 1 patient was still in complete clinical remission at week 12 in group B, and none was in group A. No adverse event related to the treatment was reported. Conclusions: This proof-of-concept pilot study did not show preliminary signal of additional avdoralimab efficiency compared with superpotent topical steroids alone.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 6","pages":"Article 100307"},"PeriodicalIF":0.0,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026724000547/pdfft?md5=cf74e6a8b3d32a0c392c744888692cbd&pid=1-s2.0-S2667026724000547-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142173031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of Circadian Clock Gene Expression in Human Skin Explants 人体皮肤切片中的昼夜节律钟基因表达分析
Pub Date : 2024-08-23 DOI: 10.1016/j.xjidi.2024.100308
William Cvammen , Michael G. Kemp

Many aspects of skin biochemistry and physiology are known to vary over the course of the 24-hour day. Traditional approaches to study circadian rhythms in the skin have employed rodents or human subjects, which limit the experimental variables that can be studied. Although explants derived from discarded surgical skin are a commonly used model in the skin biology field, circadian rhythms have yet to be examined ex vivo. In this study, using human panniculectomy skin, we used RT-qPCR to monitor the epidermal expression of 4 core circadian clock genes over the course of 1 day ex vivo. Although significant interindividual variability in overall gene expression profiles was observed, robust circadian oscillations were observed in many of the genes and individual explants. Comparison of our gene expression data with microarray data from 2 previous human-subject studies involving primarily young adult White males revealed both similarities and differences, including greater distribution in the time of day of peak expression in the skin explants. This increased variability appears to be due in part to the increased age and altered sex distribution of the donated skin. Nonetheless, our results indicate that skin explants offer an additional experimental system for studying circadian skin biology.

众所周知,皮肤生物化学和生理学的许多方面在一天 24 小时内都会发生变化。研究皮肤昼夜节律的传统方法采用啮齿类动物或人体,这限制了可研究的实验变量。虽然从废弃的手术皮肤中提取的外植体是皮肤生物学领域常用的模型,但昼夜节律尚未在体外进行研究。在这项研究中,我们利用人体胰腺切除皮肤,使用 RT-qPCR 技术监测了 4 个核心昼夜节律时钟基因在体内一天的表皮表达情况。虽然在整体基因表达谱中观察到了明显的个体差异,但在许多基因和单个外植体中观察到了稳健的昼夜节律振荡。将我们的基因表达数据与之前两项主要涉及年轻成年白人男性的人体受试者研究的芯片数据进行比较,发现两者既有相似之处,也有不同之处,其中包括皮肤外植体在一天中表达峰值的时间分布更广。这种变异性的增加似乎部分是由于捐赠皮肤年龄的增加和性别分布的改变。尽管如此,我们的研究结果表明,皮肤外植体为研究皮肤昼夜节律生物学提供了一个额外的实验系统。
{"title":"Analysis of Circadian Clock Gene Expression in Human Skin Explants","authors":"William Cvammen ,&nbsp;Michael G. Kemp","doi":"10.1016/j.xjidi.2024.100308","DOIUrl":"10.1016/j.xjidi.2024.100308","url":null,"abstract":"<div><p>Many aspects of skin biochemistry and physiology are known to vary over the course of the 24-hour day. Traditional approaches to study circadian rhythms in the skin have employed rodents or human subjects, which limit the experimental variables that can be studied. Although explants derived from discarded surgical skin are a commonly used model in the skin biology field, circadian rhythms have yet to be examined ex vivo. In this study, using human panniculectomy skin, we used RT-qPCR to monitor the epidermal expression of 4 core circadian clock genes over the course of 1 day ex vivo. Although significant interindividual variability in overall gene expression profiles was observed, robust circadian oscillations were observed in many of the genes and individual explants. Comparison of our gene expression data with microarray data from 2 previous human-subject studies involving primarily young adult White males revealed both similarities and differences, including greater distribution in the time of day of peak expression in the skin explants. This increased variability appears to be due in part to the increased age and altered sex distribution of the donated skin. Nonetheless, our results indicate that skin explants offer an additional experimental system for studying circadian skin biology.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 6","pages":"Article 100308"},"PeriodicalIF":0.0,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026724000559/pdfft?md5=0fc82d246813430bc50adaf134a4928d&pid=1-s2.0-S2667026724000559-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Tensioned Human Skin Explant Model Used for Preliminary Assessment of Chemexfoliant-Stimulated Bioeffects 用于初步评估化纤刺激生物效应的拉伸人体皮肤切口模型
Pub Date : 2024-08-23 DOI: 10.1016/j.xjidi.2024.100305
Michael J. Conneely , Jin Namkoong , Francis Allison , S. Kyoko Hirata Tsutsumi , Dominic Grussu , Ryan Willis , Kyle Henderson , Paul A. Campbell , Melissa Moy , Ewelina Lesniak , Joanna Wu , Robyn P. Hickerson
A tensioned ex vivo full-thickness human skin explant platform was used to assess the bioeffects arising from application of several commercial chemexfoliation agents. Although such treatments are well-established, and improved understanding of the underlying mechanistic processes continues to emerge, research into the optimum treatments for specific skin types/conditions is still needed for enhanced efficacy while minimizing recovery time. The 3 commercial chemexfoliation agents employed all contained trichloroacetic acid at well-defined concentrations (6, 10, and 20%) and were applied to the explants’ stratum corneum. Subsequently, measurements of dermal remodeling factors (COL1A1, ELN, HAS2, HAS3, and procollagen type I) and inflammatory marker (IL-1b) were undertaken using qPCR and immunofluorescent analyses. Statistical analysis of these data facilitated the establishment of benchmarking biological responses to these trichloroacetic acid–containing agents against untreated controls. The performance of an innovative trichloroacetic acid–free chemexfoliation agent was then measured and, upon comparison with the previous benchmarking data, indicated that dermal remodeling factors could be upregulated in fashion comparable with that of the trichloroacetic acid–containing agents but with significant suppression of inflammatory response. Our measurements thus underscore the promise of the tensioned explant over prolonged study periods and also that potentially valuable insights to guide preclinical strategies may be forthcoming from the protocol developed.
使用张力体外全厚人体皮肤外植体平台来评估应用几种商用化学去角质剂所产生的生物效应。虽然此类治疗方法已得到广泛认可,而且人们对其基本机理过程的了解也在不断加深,但仍需研究针对特定皮肤类型/条件的最佳治疗方法,以提高疗效,同时最大限度地缩短恢复时间。所采用的 3 种商用化学去角质剂都含有浓度明确的三氯乙酸(6%、10% 和 20%),并将其涂在外植体的角质层上。随后,使用 qPCR 和免疫荧光分析法测量了真皮重塑因子(COL1A1、ELN、HAS2、HAS3 和 I 型胶原)和炎症标志物(IL-1b)。对这些数据的统计分析有助于对照未处理的对照组,确定对这些含三氯乙酸制剂的生物反应的基准。然后,对一种创新的不含三氯乙酸的化学去死皮剂的性能进行了测定,并与之前的基准数据进行了比较,结果表明真皮重塑因子的上调方式与含三氯乙酸的制剂相当,但炎症反应明显受到抑制。因此,我们的测量结果表明,在长时间的研究过程中,张力外植体具有良好的前景,而且所制定的方案可能会为临床前策略提供有价值的指导。
{"title":"A Tensioned Human Skin Explant Model Used for Preliminary Assessment of Chemexfoliant-Stimulated Bioeffects","authors":"Michael J. Conneely ,&nbsp;Jin Namkoong ,&nbsp;Francis Allison ,&nbsp;S. Kyoko Hirata Tsutsumi ,&nbsp;Dominic Grussu ,&nbsp;Ryan Willis ,&nbsp;Kyle Henderson ,&nbsp;Paul A. Campbell ,&nbsp;Melissa Moy ,&nbsp;Ewelina Lesniak ,&nbsp;Joanna Wu ,&nbsp;Robyn P. Hickerson","doi":"10.1016/j.xjidi.2024.100305","DOIUrl":"10.1016/j.xjidi.2024.100305","url":null,"abstract":"<div><div>A tensioned ex vivo full-thickness human skin explant platform was used to assess the bioeffects arising from application of several commercial chemexfoliation agents. Although such treatments are well-established, and improved understanding of the underlying mechanistic processes continues to emerge, research into the optimum treatments for specific skin types/conditions is still needed for enhanced efficacy while minimizing recovery time. The 3 commercial chemexfoliation agents employed all contained trichloroacetic acid at well-defined concentrations (6, 10, and 20%) and were applied to the explants’ stratum corneum. Subsequently, measurements of dermal remodeling factors (COL1A1, ELN, HAS2, HAS3, and procollagen type I) and inflammatory marker (IL-1b) were undertaken using qPCR and immunofluorescent analyses. Statistical analysis of these data facilitated the establishment of benchmarking biological responses to these trichloroacetic acid–containing agents against untreated controls. The performance of an innovative trichloroacetic acid–free chemexfoliation agent was then measured and, upon comparison with the previous benchmarking data, indicated that dermal remodeling factors could be upregulated in fashion comparable with that of the trichloroacetic acid–containing agents but with significant suppression of inflammatory response. Our measurements thus underscore the promise of the tensioned explant over prolonged study periods and also that potentially valuable insights to guide preclinical strategies may be forthcoming from the protocol developed.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 1","pages":"Article 100305"},"PeriodicalIF":0.0,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142358495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differential Expression Analysis of Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma Proteomic Profiles Sampled with Electroporation-Based Biopsy 基于电穿孔活检取样的皮肤鳞状细胞癌和基底细胞癌蛋白质组图谱的差异表达分析
Pub Date : 2024-08-03 DOI: 10.1016/j.xjidi.2024.100304
Edward Vitkin , Julia Wise , Ariel Berl , Ofir Shir-az , Batel Gabay , Amrita Singh , Vladimir Kravtsov , Zohar Yakhini , Avshalom Shalom , Alexander Golberg
Clinical misdiagnosis between cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) affects treatment plans. We report a tissue sampling approach with molecular biopsy using electroporation. This method, coined electroporation-based biopsy (e-biopsy), enables nondestructive nonthermal permeabilization of cells in the skin for vacuum-assisted extraction of biomolecules. We used e-biopsy for ex vivo proteome extraction from 3 locations per patient in 21 cSCC, 20 BCC, and 7 actinic keratosis human skin samples. Using liquid chromatography with tandem mass spectrometry, we identified 5966 proteins observed with nonzero intensity in at least 1 sample. The intrapatient Pearson correlation of 0.888 ± 0.065 for patients with BCC, 0.858 ± 0.077 for patients with cSCC, and 0.876 ± 0.116 for those with solar actinic keratosis indicates high consistency of the e-biopsy sampling. The mass spectra presented significantly different proteome profiles for cSCC, BCC, and solar actinic keratosis, with several hundreds of proteins differentially expressed. Notably, our study showed that proteomes sampled with e-biopsy from cSCC and BCC lesions are different and that proteins of CRNN, SULT1E1, and ITPK1 genes are significantly overexpressed in BCC in comparison with those in cSCC. Our results provide evidence that the e-biopsy approach could potentially be used as a tool to support cutaneous lesions classification with molecular pathology.
皮肤鳞状细胞癌(cSCC)和基底细胞癌(BCC)之间的临床误诊会影响治疗计划。我们报告了一种利用电穿孔技术进行分子活检的组织取样方法。这种方法被称为基于电穿孔的活检(e-biopsy),它能对皮肤中的细胞进行非破坏性的非热渗透,以真空辅助提取生物分子。我们使用电子活检技术从 21 例 cSCC、20 例 BCC 和 7 例光化性角化病人体皮肤样本中的每个患者的 3 个部位进行体外蛋白质组提取。通过液相色谱-串联质谱法,我们在至少一个样本中鉴定出了 5966 种强度不为零的蛋白质。BCC 患者的患者间皮尔逊相关性为 0.888 ± 0.065,cSCC 患者的患者间皮尔逊相关性为 0.858 ± 0.077,日光性角化病患者的患者间皮尔逊相关性为 0.876 ± 0.116。质谱显示,cSCC、BCC 和日光性角化病的蛋白质组特征明显不同,有数百种蛋白质表达不同。值得注意的是,我们的研究表明,通过电子活检从 cSCC 和 BCC 病变中提取的蛋白质组是不同的,与 cSCC 相比,CRNN、SULT1E1 和 ITPK1 基因的蛋白质在 BCC 中明显过表达。我们的研究结果提供了证据,证明电子活组织检查法可作为一种工具,用于支持皮肤病变的分子病理学分类。
{"title":"Differential Expression Analysis of Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma Proteomic Profiles Sampled with Electroporation-Based Biopsy","authors":"Edward Vitkin ,&nbsp;Julia Wise ,&nbsp;Ariel Berl ,&nbsp;Ofir Shir-az ,&nbsp;Batel Gabay ,&nbsp;Amrita Singh ,&nbsp;Vladimir Kravtsov ,&nbsp;Zohar Yakhini ,&nbsp;Avshalom Shalom ,&nbsp;Alexander Golberg","doi":"10.1016/j.xjidi.2024.100304","DOIUrl":"10.1016/j.xjidi.2024.100304","url":null,"abstract":"<div><div>Clinical misdiagnosis between cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) affects treatment plans. We report a tissue sampling approach with molecular biopsy using electroporation. This method, coined electroporation-based biopsy (e-biopsy), enables nondestructive nonthermal permeabilization of cells in the skin for vacuum-assisted extraction of biomolecules. We used e-biopsy for ex vivo proteome extraction from 3 locations per patient in 21 cSCC, 20 BCC, and 7 actinic keratosis human skin samples. Using liquid chromatography with tandem mass spectrometry, we identified 5966 proteins observed with nonzero intensity in at least 1 sample. The intrapatient Pearson correlation of 0.888 ± 0.065 for patients with BCC, 0.858 ± 0.077 for patients with cSCC, and 0.876 ± 0.116 for those with solar actinic keratosis indicates high consistency of the e-biopsy sampling. The mass spectra presented significantly different proteome profiles for cSCC, BCC, and solar actinic keratosis, with several hundreds of proteins differentially expressed. Notably, our study showed that proteomes sampled with e-biopsy from cSCC and BCC lesions are different and that proteins of <em>CRNN</em>, <em>SULT1E1</em>, and <em>ITPK1</em> genes are significantly overexpressed in BCC in comparison with those in cSCC. Our results provide evidence that the e-biopsy approach could potentially be used as a tool to support cutaneous lesions classification with molecular pathology.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 6","pages":"Article 100304"},"PeriodicalIF":0.0,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142446133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JID innovations : skin science from molecules to population health
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1